Back to Search
Start Over
Use of Nicergoline as Adjunctive Treatment of Neurotrophic Keratitis in Routine Clinical Practice: A Case Series.
- Source :
-
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2022 Oct-Nov; Vol. 30 (7-8), pp. 1926-1930. Date of Electronic Publication: 2021 Oct 12. - Publication Year :
- 2022
-
Abstract
- Purpose: To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis (NK).<br />Methods: A prospective case series review was performed in 14 patients with NK who started treatment with nicergoline as an off-label prescription from January to November 2020. Patients with a epithelial defect or corneal ulcer due to NK were treated with oral nicergoline.<br />Results/serial Cases: Complete corneal healing was observed in 10 (71.4%) of the 14 patients after 25.6 ± 26.60 days (range 7-90) with nicergoline. In three (21.5%) patients wound healing was not achieved, and one patient (7.1%) was lost to follow-up. The mean time between diagnosis and the starting of nicergoline was 10.92 ± 8.85 days (0-28). No adverse effects of nicergoline were observed.<br />Conclusion: Nicergoline as an adjunctive treatment for NK showed a potential use in the healing of epithelial defect in real-life clinical practice.
- Subjects :
- Humans
Nicergoline
Corneal Ulcer diagnosis
Corneal Ulcer drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-5078
- Volume :
- 30
- Issue :
- 7-8
- Database :
- MEDLINE
- Journal :
- Ocular immunology and inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 34637676
- Full Text :
- https://doi.org/10.1080/09273948.2021.1976214